GREENER Pharmaceuticals for More Sustainable Healthcare
Publikation: Beiträge in Zeitschriften › Übersichtsarbeiten › Forschung
Standard
GREENER Pharmaceuticals for More Sustainable Healthcare. / Moermond, Caroline T.A.; Puhlmann, Neele; Brown, A. Ross et al.
in: Environmental Science and Technology Letters, Jahrgang 9, Nr. 9, 13.09.2022, S. 699-705.Publikation: Beiträge in Zeitschriften › Übersichtsarbeiten › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - GREENER Pharmaceuticals for More Sustainable Healthcare
AU - Moermond, Caroline T.A.
AU - Puhlmann, Neele
AU - Brown, A. Ross
AU - Owen, Stewart F.
AU - Ryan, Jim
AU - Snape, Jason
AU - Venhuis, Bastiaan J.
AU - Kümmerer, Klaus
N1 - Publisher Copyright: © 2022 American Chemical Society.
PY - 2022/9/13
Y1 - 2022/9/13
N2 - Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.
AB - Medicines are essential to human health but can also impact the aquatic and terrestrial environment after use by patients and release via excreta into wastewater. We highlight the need for a GREENER approach to identify and meet important environmental criteria, which will help reduce the impact of medicinal residues on the environment. These criteria include effect reduction by avoiding nontarget effects or undesirable moieties, exposure reduction via lower emissions or environmental (bio)degradability, no PBT (persistent, bioaccumulative, and toxic) substances, and risk mitigation. With all of these criteria, however, patient health is of primary importance as medicines are required to be safe and efficacious for treating diseases. We discuss the feasibility of including these criteria for green by design active pharmaceutical ingredients in the process of drug discovery and development and which tools or assays are needed to accomplish this. The integrated GREENER approach can be used to accelerate discussions about future innovations in drug discovery and development.
KW - criteria
KW - drug discovery and development
KW - environment
KW - pharmaceuticals
KW - sustainability
KW - water quality
KW - Chemistry
UR - http://www.scopus.com/inward/record.url?scp=85137285228&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/6bb945e1-bc59-31a5-a26f-abde5388cf33/
U2 - 10.1021/acs.estlett.2c00446
DO - 10.1021/acs.estlett.2c00446
M3 - Scientific review articles
C2 - 36118957
AN - SCOPUS:85137285228
VL - 9
SP - 699
EP - 705
JO - Environmental Science and Technology Letters
JF - Environmental Science and Technology Letters
SN - 2328-8930
IS - 9
ER -